Associations between longitudinal pretreatment BMI and neutrophil/lymphocyte ratio(NLR) and progression-free(PFS) and overall survival(OS) in advanced NSCLC patients treated with single agent anti-PD-1/anti-PDL1 monoclonal antibodies(mAbs).

Megan Randall,Sanjib Basu,Revathi Kollipara,Marta Batus,Philip Bonomi,Hita Moudgalya,Jeffrey A. Borgia,Mary J. Fidler

Associations between longitudinal pretreatment BMI and neutrophil/lymphocyte ratio(NLR) and progression-free(PFS) and overall survival(OS) in advanced NSCLC patients treated with single agent anti-PD-1/anti-PDL1 monoclonal antibodies(mAbs).

2021

Megan Randall
Sanjib Basu
Revathi Kollipara
Marta Batus
Philip Bonomi
Hita Moudgalya
Jeffrey A. Borgia
Mary J. Fidler

e21189Background: Several parameters that have been associated with outcomes in patients with metastatic NSCLC treated with anti-PD1/PDL1 mAbs include tumor PD-L1 expression, tumor mutational burde...

Keywords:

Medicine
single agent
Lymphocyte
in patient
overall survival
Cancer research
anti pd 1
Monoclonal antibody

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations